Application of Ozanimod in preparation of medicine for treating muscular dystrophy

A technology for muscular dystrophy and muscular dystrophy, applied in the field of medicine, can solve problems such as adverse reactions of patients, gene therapy methods are in the research stage, etc., and achieve the effect of reducing inflammation, improving muscle weakness and/or muscle atrophy

Pending Publication Date: 2022-03-01
CHINA PHARM UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Duchenne muscular dystrophy is a genetic disease caused by gene mutations. Gene therapy may eventually be an effective way for Duchenne muscular dystrophy, but so far gene therapy is still in the research stage
At present, the ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Ozanimod in preparation of medicine for treating muscular dystrophy
  • Application of Ozanimod in preparation of medicine for treating muscular dystrophy
  • Application of Ozanimod in preparation of medicine for treating muscular dystrophy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] 1- Construction of animal model:

[0021] mdx mice are DMD gene defects, leading to the absence of dystrophin protein, a well-recognized model mouse for the study of Duchenne / Bein muscular dystrophy. Compared with the wild control group, mdx mice had abnormal muscle tissue morphology; markers of muscle degeneration, serum levels of creatine kinase and lactate dehydrogenase increased; a large number of macrophages accumulated in muscle tissue, accompanied by fibrosis and The occurrence of necrosis. The experimental animals used in the present invention are mdx transgenic mice named (C57BL / 10ScSnJNju-DmdDMD / Nju), purchased from Nanjing Jicui Yaokang Company.

[0022] 2- Animal grouping and administration

[0023] The present invention administers ozanimod to mdx mice by intragastric administration, at a dose of 1 mg / kg / day, and feeds them for 42 days. The muscle grip strength of the mice was measured on the 40th day of administration, the rod hanging time of the mice w...

Embodiment 2

[0042] Gait analysis: the gait analysis and statistics of the mdx mice after the 41st day of administration in Example 1 were carried out using the ink method. The stride length and stride width of the front and hind limbs of mice in each group were recorded respectively. The average value of each test was taken 3 times, and the results are shown in Table 4.

[0043] Table 4 Statistical results of mdx mouse gait experiment

[0044] group normal group DMD model group ozanimod treatment group Forelimb stride length (cm) 6.5±0.5 5.0±0.7 *

6.1±0.2 #

Hindlimb stride length (cm) 6.9±0.5 5.3±0.6 *

6.2±0.5 #

Forelimb stride width (cm) 2.0±0.3 1.7±0.1 *

1.8±0.1 #

Hind leg width (cm) 2.6±0.3 2.9±0.5 *

2.5±0.2 #

[0045] * P# P<0.05 compared with DMD model group.

[0046] The results showed that the forelimb step width of the mice in the DMD model group became narrower, the hindlimb step length became shorter ...

Embodiment 3

[0048] After 42 days of administration, the mdx mice in Example 1 were euthanized on the 43rd day after overnight fasting for 12 hours, blood was taken from the inguinal vein, centrifuged at 3500 rpm for 10 minutes, and the upper serum was taken to measure serum creatine kinase (CK) and lactic acid Dehydrogenase (LDH) content. Then the gastrocnemius, tibialis anterior muscle, and diaphragm were dissected and quickly frozen in liquid nitrogen, and transferred to a minus 80 refrigerator for later use. The content of serum CK and LDH and the weight of the first few muscles of the tibia are shown in Table 5.

[0049] Table 5 mdx mouse tibialis anterior muscle weight

[0050] group normal group DMD model group ozanimod treatment group CK(U / L) 1942.5±550.3 18900.0±7145.6 *

16524.0±4122.5 #

LDH(U / L) 542.5±196.8 5824.3±2019.8 *

2634.3±600.3 Tibialis anterior muscle weight (mg) 52.2±3.9 63.3±6.8 *

55.3±6.5 #

[0051] * P# P<...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of Ozanimod in preparation of a medicine for treating muscular dystrophy, and belongs to the field of medicine. An internationally recognized DMD gene knockout mouse, namely an mdx mouse, is used as a muscular dystrophy model, and the treatment effect of ozanimod on myasthenia and amyotrophy caused by muscular dystrophy is investigated on the mdx mouse. The influence of ozanimod on myasthenia and amyotrophy caused by muscular dystrophy is systematically studied from the aspects of pharmacodynamics, behavioristics, molecular biology and the like, and the result shows that ozanimod can reverse the deficiency of muscle fibers and enhance the strength and function of skeletal muscles.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of Ozanimod in the preparation of medicine for treating muscular dystrophy. Background technique [0002] ozanimod (RPC1063, figure 1 ) is an orally bioavailable S1P receptor modulator with potential anti-inflammatory and immunomodulatory activities for the treatment of relapsing multiple sclerosis and inflammatory bowel disease. After oral administration, ozanimod selectively targets and binds to S1PR1 on lymphocytes, and induces S1PR1 internalization and degradation. This causes lymphocytes to become sequestered in the lymph nodes. By preventing lymphocyte efflux, ozanimod reduces the number of circulating peripheral lymphocytes and the infiltration of lymphocytes into target tissues, which prevents lymphocyte-mediated immune responses and may reduce inflammation. S1PR1 is a G protein-coupled receptor that plays a key role in the migration of lymphocytes. The regulat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4245A61P21/00
CPCA61K31/4245A61P21/00
Inventor 江振洲黄小菲俞沁玮范书生洪晖涛赖竹兰李春杰
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap